Immunomodulatory Drugs (IMiDs) in Multiple Myeloma

E-ISSN： 1873-5576|17|9|846-857

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.17, Iss.9, 2017-10, pp. : 846-857

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies

By Schafer Peter H

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 10, 2012-07 ,pp. : 1541-1542

Informa Healthcare

Access to resources Recommend Favorite

Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies

By Vallet Sonia Witzens-Harig Mathias Jaeger Dirk Podar Klaus

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 4, 2012-03 ,pp. : 473-494

Informa Healthcare

Access to resources Recommend Favorite

Immunomodulatory Drugs (IMiDs™): A New Treatment Option for Myelodysplastic Syndromes

Current Pharmaceutical Biotechnology, Vol. 7, Iss. 5, 2006-10 ,pp. : 339-342

Bentham Science Publishers

Access to resources Recommend Favorite

Thalidomide Derived Immunomodulatory Drugs (IMiDs) as Potential Therapeutic Agents

Current Drug Targets - Immune, Endocrine & Metabolic Disorders, Vol. 3, Iss. 3, 2003-09 ,pp. : 181-186

Bentham Science Publishers

Access to resources Recommend Favorite

Immunomodulatory drugs in multiple myeloma

By Zangari Maurizio Elice Francesca Tricot Guido

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 11, 2005-11 ,pp. : 1411-1418

Informa Healthcare

Access to resources Recommend Favorite